Not All is Dry with Dry AMD
And now…finally…some good news in dry AMD! Geographic atrophy (GA) remains a significant unmet need that has been met with great attention by investigators and industry. However, until now, all…
Lampalizumab Does Not Meet Primary Endpoint
Genentech reported yesterday that lampalizumab did not meet the primary endpoint in SPECTRI, one of the two parallel Phase III clinical trials investigating lampalizumab injections for the treatment of geographic…
New Macular Hole Technique: ILM Repositioning
The Surgical Technique section is one of the highlights of RETINA. New and innovative techniques are introduced in this section with accompanying surgical videos. It’s certainly a section that I…
HAWK/HARRIER: Coming in for a Landing
In June, Novartis announced results from HAWK and HARRIER, two phase III clinical trials comparing brolocizumab (formerly RTH258) to aflibercept for the treatment of wet AMD. The primary endpoints were…
ASRS 2017 Tuesday (Day 5)
The final day of the ASRS annual meeting in Boston started off strong with hereditary retinal disease and genetic symposium. Next, Mark Humayan led an informative panel discussion reminding us…
ASRS 2017 WinR Special: Interview with Zelia Correa, MD, PhD
Women in Retina: a profile of Zelia M. Correa, MD, PhD Interviewed by Nika Bagheri, MD What is your story? How did you become a retinal surgeon, ocular oncologist, and…
ASRS 2017 Monday (Day 4): OCTA
The Imaging Expert Panel on Monday morning brought together some of the premier innovators in imaging, providing insights into upcoming developments in OCT Angiography. They introduced new and exciting work…
ASRS 2017 Monday (Day 4): Neovascular AMD
Day 4 of the ASRS annual meeting has provided us with even more clinically relevant information regarding neovascular age-related macular degeneration (nvAMD) and retinal detachments (RDs). Both Geoffrey Emerson and…